🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 13 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/02/2011 54,76 55,16 54,63 54,94 +0,11% 0,97% 3.399.300
07/02/2011 55,23 55,33 54,76 54,88 -0,58% 1,03% 3.861.900
04/02/2011 55,62 55,62 54,74 55,20 -0,45% 1,58% 4.569.900
03/02/2011 55,27 55,64 55,00 55,45 -0,32% 1,16% 4.227.000
02/02/2011 55,14 55,65 54,79 55,63 -0,14% 1,56% 5.353.400
01/02/2011 55,23 55,88 55,11 55,71 +1,14% 1,39% 5.615.800
31/01/2011 55,22 55,46 54,85 55,08 -0,38% 1,10% 6.021.300
28/01/2011 56,61 56,61 55,11 55,29 -2,11% 2,65% 6.928.300
27/01/2011 56,46 56,87 56,06 56,48 +0,00% 1,43% 4.686.000
26/01/2011 57,27 57,47 56,32 56,48 -1,19% 2,01% 6.833.600
25/01/2011 56,91 58,19 56,74 57,16 -0,23% 2,55% 8.944.000
24/01/2011 57,06 57,87 56,81 57,29 +0,56% 1,86% 5.647.800
21/01/2011 57,41 57,41 56,74 56,97 -0,59% 1,17% 6.032.900
20/01/2011 56,78 57,65 56,68 57,31 +0,58% 1,71% 6.313.600
19/01/2011 57,21 57,43 56,60 56,98 -0,54% 1,45% 5.771.500
18/01/2011 56,40 57,34 56,35 57,29 +1,40% 1,76% 10.611.900
14/01/2011 56,05 57,28 56,05 56,50 +0,32% 2,19% 5.893.700
13/01/2011 56,72 57,00 56,23 56,32 -0,93% 1,36% 4.660.300
12/01/2011 56,30 56,92 56,05 56,85 +1,17% 1,55% 4.566.400
11/01/2011 56,55 56,88 56,09 56,19 -0,44% 1,40% 5.863.900
10/01/2011 56,47 56,95 56,21 56,44 -0,95% 1,31% 4.758.900
07/01/2011 56,50 57,19 56,46 56,98 +0,76% 1,29% 4.680.800
06/01/2011 56,68 57,18 56,07 56,55 -0,32% 1,96% 3.561.400
05/01/2011 56,46 57,16 56,40 56,73 -0,04% 1,35% 4.552.000
04/01/2011 55,77 57,24 55,69 56,75 +2,16% 2,78% 8.429.500
03/01/2011 55,20 56,28 55,18 55,55 +1,18% 1,99% 5.453.300
31/12/2010 55,47 55,61 54,77 54,90 -1,13% 1,51% 3.997.500
30/12/2010 55,69 56,17 55,46 55,53 -0,61% 1,27% 3.414.000
29/12/2010 56,15 56,37 55,87 55,87 -0,16% 0,89% 3.601.700
28/12/2010 56,38 56,56 55,94 55,96 -0,85% 1,10% 4.025.200